Veru (VERU)
Develops oral candidates for obesity-related body composition and atherosclerotic inflammation.
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Canaccord Genuity's 46th Annual Growth Conference, in Boston, Massachusetts, on August 12, 2026 at 2:00 pm – 2:25 pm Eastern Daylight Time.
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the completion of enrollment in the Phase 2b PLATEAU clinical study to evaluate the effect of oral enobosarm 3 mg versus placebo on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in ~200 older patients (age ≥ 65 years) who have obesity (BMI ≥ 35) and are initiating semaglutide treatment for weight reduction. The interim analysis results from the study are expected in the first quarter of calendar year 2027 with final topline clinical data expected in the fourth quarter of calendar year 2027.
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit, and the Pre-Conference Workshop Day taking place on July 14-16, 2026, in Boston, Massachusetts.
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, May 13, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 second quarter financial results and to provide a business update.
Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.64 and traded as low as $2.28. Veru shares last traded at $2.31, with a volume of 66,482 shares changing hands. Analyst Ratings Changes A number of
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell?
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.69 and traded as low as $2.39. Veru shares last traded at $2.43, with a volume of 18,400 shares traded. Wall Street Analysts Forecast Growth Several research firms
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.81 and traded as low as $2.19. Veru shares last traded at $2.23, with a volume of 47,526 shares traded. Wall Street Analyst Weigh In VERU has
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide -- -- Interim analysis expected in the first quarter calendar year 2027-- -- Final topline clinical data expected in the fourth quarter calendar year 2027--
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update.
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.16 and traded as low as $2.38. Veru shares last traded at $2.39, with a volume of 70,439 shares traded. Analysts Set New Price Targets Separately, Weiss Ratings
Veru to Report Fiscal Year 2025 Financial Results on December 17th
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update.
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia.